Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...
Recently, Shanghai Hi-dolphin COFE+ Robot Café, successfully completed 4 financing rounds, quickly becoming a new popular ...
Sales Factory will participate in its 23rd annual CreateAthon, a 24-hour "creative marathon," during which the agency will collaborate with 26 nonprofits to deliver 50 impactful marketing projects.
Fintel on MSN9h
Leerink Partners Upgrades Gilead Sciences (GILD)Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback